Craft

PolyPeptide Group

Stock Price

CHF28.9

2024-10-29

Market Capitalization

CHF961.5 M

2024-10-29

Revenue

€389.3 M

FY, 2025

PolyPeptide Group Summary

Company Summary

Overview
PolyPeptide Group is a contract development and manufacturing organization (CDMO) that supports pharmaceutical and biotechnology companies. It produces proprietary and generic GMP-grade peptide-based generics, custom research grade peptides, stable and radioactive isotope labelled peptides, and organic molecules. The company also provides pre-GMP development, GMP compliance, production, quality control and assurance, GMP inspections, and regulatory support services.
Type
Public
Status
Active
Founded
1952
HQ
Baar, CH | view all locations
Website
https://www.polypeptide.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Juan Jose Gonzalez

    Juan Jose Gonzalez, Chief Executive Officer

  • Monika Casanova

    Monika Casanova, Chief Human Resources Officer

  • Christina del Vecchio

    Christina del Vecchio, General Counsel

  • Patrick Aebischer

    Patrick Aebischer, Vice Chairman, Lead Independent Director

Operating MetricsView all

Phase III Trials Products

31
3.3%

H1, 2023

Projects

226
3.7%

H1, 2023

Phase II Trials Products

37
2.6%

FY, 2022

LocationsView all

7 locations detected

  • Baar, ZG HQ

    Switzerland

    Neuhofstrasse 24

  • San Diego, CA

    United States

    9395 Cabot Dr

  • Torrance, CA

    United States

    365 Maple Ave

  • Braine-l'Alleud, Région Wallonne

    Belgium

    Chau. de Tubize 297

  • Strasbourg, Grand Est

    France

    7 Rue de Boulogne

  • Thane, MH

    India

    K-28, Additional MIDC, Anand Nagar, Ambernath (East)

and 1 others

PolyPeptide Group Financials

Summary Financials

Revenue (FY, 2025)
€389.3M
Gross profit (FY, 2025)
€103.3M
Net income (FY, 2025)
(€21.2M)
Cash (FY, 2025)
€74.6M
EBIT (FY, 2025)
€8.7M
Enterprise value
$1.0B

Footer menu